GlassScriptPhysician profile
Robert W Weisenthal
NPI 1508957507
$2,568.89
in general payments reported to CMS, 2019-2025
13 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $46.37 · 2021: $31.30 · 2022: $191 · 2023: $1,350 · 2024: $160 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Food and Beverage | $773.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,072.76 | 2023-2024 | Kxl System (Not Refurbished), Photrexa |
| Alcon Vision LLC | $778.89 | 2019-2025 | Clareon, Hydrus Microstent, Voyager Dslt |
| Dompe US, INC. | $330.06 | 2019-2024 | Oxervate |
| Biotissue Holdings INC. | $163.46 | 2022-2025 | |
| Ocular Therapeutix, INC. | $56.08 | 2022-2024 | Dextenza |
| Harrow Eye, LLC | $37.66 | 2024 | |
| Horizon Therapeutics Plc | $25.82 | 2023 | Tepezza |
| Rxsight INC | $22.39 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abb Con-Cise Optical Group LLC | $17.82 | 2025 | Spectacle Lenses |
| Oyster Point Pharma, INC. | $17.68 | 2024 | Ryzumvi, Tyrvaya |
| Abbvie INC. | $13.95 | 2022 | |
| Kala Pharmaceuticals, INC. | $12.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weisenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.